Fig. 3
Characterizations of FZ/MER-AgMOF@Bm. (A) TEM images of AgMOF, LPS-BMSC membrane vesicles (BMSCm) and AgMOF@Bm. (B) SEM elemental mapping images of AgMOF. (C) Relative quantification of elements in Figure B. (D) FTIR spectra of AgMOF, 2-methylimidazole and AgNO3. (E) XPS survey spectra of FZ/MER-AgMOF and AgMOF. (F) SDS‑PAGE protein assessment for AgMOF, BMSCm and AgMOF@Bm. (G) DLS analysis of hydrodynamic diameter and zeta potential for FZ/MER-AgMOF@Bm, BMSCm and FZ/MER-AgMOF. (H) EE and LE of FPS-ZM1 and meropenem in AgMOF. (I) Cumulative release rate of FPS-ZM1 and meropenem from FZ/MER-AgMOF@Bm at pH 6.5 or pH 7.4. (J) Hemolysis ratios of erythrocyte’ suspensions treated with different concentrations of AgMOF or FZ/MER-AgMOF@Bm for 2 h. (K) EE and LE of FZ/MER-AgMOF@Bm. (L) The cell viability (%) of RAW264.7 treated with Ag-MOF or FZ/MER-AgMOF@Bm for 24 h. (M) Images of RAW264.7 incubated with FZ/MER-AgMOF@Bm or AgMOF for 12 h. Scale bar: 50 μm. Data are derived from three independent experiments and presented as mean ± SEM in the bar graphs. Values of controls were normalized to 1. *P < 0.05, **P < 0.01, ***P < 0.001, ns: not significant